Semaglutide and median survival in female mice: a September 2026 Nature report
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description reports a September 2026 Nature study in which female mice given semaglutide late in life had a median survival of 834 days versus 742 days. The creator stresses that one sex, one inbred strain and a mouse dosing protocol do not establish longer human lifespan. [1]
The description reports median survival of 834 days versus 742 days in female mice receiving late-life semaglutide, a difference of about 92 days or 12%. [1]
The creator states that one sex, one inbred strain and a mouse dosing protocol do not establish longer human lifespan or a new anti-aging indication. [1]
The description says visuals are labeled illustrative stock footage and that people and locations in stock footage are not represented as case participants, trial participants or the named companies. [1]
Reported mouse survival difference with late-life semaglutide
According to the description, a September 2026 Nature study reported median survival of 834 days in female mice receiving late-life semaglutide versus 742 days in the comparison group. The creator states the difference is about 92 days, or 12%. The description does not name the comparison group beyond this contrast, so the exact comparator is not specified here. [1]
Creator's caution on mice versus human lifespan
The description states that one sex, one inbred strain and a mouse dosing protocol do not establish longer human lifespan or a new anti-aging indication. It labels the content as general research reporting and says treatment decisions belong with a qualified clinician. The creator also asks viewers about anti-aging claims regarding weight-loss drugs. [1]
Description-only scope and illustrative visuals
The description notes that visuals are labeled illustrative stock footage and that people and locations in stock footage are not represented as case participants, trial participants or the named companies. Charts are described as original explanatory graphics, and covers with named people as AI-assisted photo composites. The description does not report the study's methods, sample size or follow-up beyond the survival figures. [1]
Context & limits
This explainer is based only on the video description; the video and transcript were not reviewed. The description gives survival figures but not the study's methods, sample size, follow-up or exact comparator arm. It is general research reporting, not medical advice.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
median survival of 834 days versus 742
do not establish longer human lifespan
not represented as case participants, trial participants
About this video
Creator description · original textText language: English
THE VITAL YEARS · 2 min · Source published: 2026-09-30
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.